Diabetic nephropathy is a major cause of diabetesrelated morbidity and mortality; however the clinical course of the disease and the renal prognosis is highly variable among individuals. The current review will discuss the genetic influence on the development of end stage renal disease (ESRD) in diabetic patients and potential improvements to the current treatment strategy to slow the loss of kidney function in these patients. In this first part, the growing evidence that glucose-induced activation of the intra-renal and systemic renin-angiotensin systems plays an essential role in processes leading to destruction of renal function is summarised. Genetic variations, especially the angiotensin-converting enzyme (ACE)/ID polymorphisms in the gene coding for ACE, are involved in activation of the renin-angiotensin system and seem to influence the clinical course of diabetic nephropathy during treatment with ACE inhibitors. In addition, this polymorphism may interact with other polymorphisms within the reninangiotensin system, leading to high risk of ESRD. As new genetic approaches and methods develop, further understanding of diabetic nephropathy will evolve and genotyping will help prevent ESRD in diabetic patients.
Introduction
Diabetic nephropathy is the leading cause of end stage renal disease (ESRD) in many countries and a main cause of diabetes-related morbidity and mortality. 1 Diabetic nephropathy is characterised by series of ultrastructural changes in all renal compartments. The changes include glomerular basement thickening, glomerular and tubular hypertrophy, mesangial expansion, glomerulosclerosis and tubulointerstitial fibrosis. 2 Key clinical manifestations accompanying the structural changes are: increasing urinary albumin excretion to manifest albuminuria, elevated blood pressure, declining kidney function, culminating in the development of uraemia and ESRD. 2 These processes are initially triggered by a combination of haemodynamic and metabolic mechanisms, growth factors, cytokines and genetic susceptibility linked to the diabetic state, per se, as reviewed by several authors. [2] [3] [4] [5] [6] In later stages, haemodynamic and non-haemodynamic renal adaptations follow a common pathway for noxious stimuli in the kidney, which eventually leads to destroyed kidney function if renoprotective treatment is not introduced. 7-10 Activation of the renin-angiotensin system (RAS) is of key importance in both the initiation and the later stages of the diabetic kidney disease.
Elevated systemic blood pressure and albuminuria are the most important non-genetic risk factors for a fast decline in renal function in patients with diabetic nephropathy. 2, [11] [12] [13] In accordance, lowering blood pressure and albuminuria with antihypertensive treatment is the most powerful tool to slow down the progression of diabetic nephropathy. 2, 11 The lower the blood pressure and albuminuria levels after initiation of antihypertensive therapy, especially blockade of the RAS, the better long-term course of diabetic nephropathy. 2, 11, [14] [15] [16] [17] [18] [19] Therefore, reduction in albuminuria after the start of antihypertensive treatment may serve as a surrogate endpoint for monitoring treatment efficacy and long-term prognosis in diabetic nephropathy. 9, 18, 20 Despite a dramatically improved prognosis in diabetic nephropathy during the past 25 years, [21] [22] [23] [24] the current mean loss of glomerular filtration rate (GFR) in Type 1 diabetic patients with diabetic nephropathy is still 3-4 times higher than normal, with a range from 0 to 24 ml/min/year. 2, 13 As a consequence, some patients will reach dialysis within five years of onset of diabetic nephropathy, whereas others will die with well-preserved kidney function.Therefore, major determinants of the course of diabetic nephropathy (risk factors) are still to be described in order to understand the pathogenesis of the disease and to identify highrisk individuals. Together with more effective treatment modalities, this is essential to reach the ultimate goal, improvement of prognosis in diabetic patients.
The major aim of this review is two-fold: a) Part I: to identify specific genetic risk factors, especially within the RAS, determining the individual rate of progression of kidney disease and response to treatment in Type 1 diabetic patients with diabetic nephropathy. b) Part II (to be published in the next issue of JRAAS): to investigate whether the current treatment strategy of RAS blockade in diabetic nephropathy with angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs) can be optimised by combining the two drug classes (dual blockade). Furthermore, new aspects of short-term hyperglycaemia on haemodynamics and the RAS will be briefly discussed (part I). 
Experimental evidence for renal RAS activation
Evidence for intrarenal RAS activation is well established from experimental studies.The importance of haemodynamic abnormalities in renal disease was originally demonstrated using micropuncture techniques in single nephrons of rats.
Augmented intraglomerular pressure was established as an essential factor in the mediation of glomerular injury in various renal diseases, including diabetes. 7, 8 Micropuncture of diabetic rats revealed abnormalities which include preferential afferent renal arteriolar vasodilatation, increased glomerular pressure and flows and increased GFR. 36 Administration of an ACE-I lowered the intraglomerular pressure and was associated with reduced renal injury 36 and, since reduction in intraglomerular pressure was more effective when using ACE-I compared with other antihypertensives, 27 the haemodynamic importance of the intrarenal RAS was strongly indicated.The haemodynamic alterations could not, however, predict the subsequent degree of sclerosis development in individual glomeruli and therefore additional factors were proposed. 37 Such non-haemodynamic mechanisms which are significant for glomerular growth and glomerulosclerosis in various renal diseases are also very likely, to be at least partly mediated via Ang II, as reviewed by several authors. 10, 38, 39 Several non-haemodynamic actions of Ang II in diabetic models have been demonstrated. As reviewed, 6, 40, 41 studies in cell culture systems and in animals indicate that a highglucose milieu increases Ang II and growth hormone production by renal cells, leading to the production of extracellular matrix. One mechanism may be a direct effect of glucose causing activation of the expression of angiotensinogen gene, as shown in rats. 42 An important pathway seems to be Ang II-stimulated generation of transforming growth factor-β‚ (TGF-β), in addition to other cytokines mediating matrix production. 6 Findings in several models of renal disease suggest an even more complicated picture, with redistribution and various changes in activity and sensitivity of RAS components in different renal compartments, with the tubular segments as the primarily activated site. 6, 9, 43, 44 Furthermore, dissociation between high intrarenal and low systemic RAS activity has been demonstrated in several animal models, as reviewed by Taal and Brenner. 45 
Evidence of renal RAS activation from human studies
Human studies have also indirectly demonstrated 2
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Figure 1
The renin-angiotensin system. * Compounds with genetic polymorphisms discussed in text 49 and an enhanced increase in renal blood flow (+ decreased vascular resistance) in response to ARB treatment was seen, in addition to a blunted effect of Ang II. 50 Interestingly, this indicates similar renal effects of elevated glucose and Ang II infusion in diabetic patients under these conditions, suggesting a direct link between the two and supporting the idea of intrarenal RAS activation associated with hyperglycaemia.A study of Type 2 diabetic patients with nephropathy also demonstrated increased renal perfusion in response to ARB therapy, compared with healthy subjects. 51 An interesting study of intrarenal haemodynamics calculated from arterial blood pressure and urinary sodium clearance (pressure natriuresis curves) indicated higher resistance of efferent arterioles and glomerular pressure in Type 2 patients with microalbuminuria compared with those with normoalbuminuria. 52 Both glomerular pressure and albuminuria declined in response to ACE-I treatment, in accordance with a role of the RAS in the pathogenesis of diabetic nephropathy. 52 Finally, direct evidence of intrarenal RAS activation came from a study demonstrating increased ACE staining in kidney biopsies from patients with diabetic nephropathy compared with healthy kidney transplant donors. 53 Furthermore, as described above, long-term RAS blockade offers renoprotection and delays ESRD, independent of blood pressure reduction in patients with diabetic nephropathy. [14] [15] [16] [28] [29] [30] [31] [32] [33] Glucose, systemic haemodynamics and the RAS As in animal studies, human studies of the systemic RAS in diabetes indicate some degree of dissociation from the intrarenal system. Decreased activity/levels of circulating renin, Ang II and aldosterone in diabetic patients with and without nephropathy have frequently been demonstrated, 51, [54] [55] [56] although increased levels were also found in some studies. [56] [57] [58] This paradox of a low/normal systemic and an activated intrarenal RAS may be a result of suppression of renin release via negative feedback by intrarenal Ang II (short loop) and the associated sodium retention (long loop). 51, 56 However, several studies focussing on changes in systemic RAS components during different degrees of hyperglycaemia in early diabetes demonstrated an activating effect of glucose. 49, 59 In agreement, elevation of ACE has been demonstrated in diabetic patients, 60 with a further increase seen in patients with complications. [60] [61] [62] The functional significance of the increase in circulating RAS components, in addition to the direct effect of hyperglycaemia, on systemic haemodynamic parameters is poorly understood.
Since systemic blood pressure is such an important factor for initiation and progression of diabetic nephropathy, we became interested in whether hyperglycaemia (acute, sub-acute or chronic), per se, induces an increase in systemic blood pressure. Evidence supporting this theory came from population-based studies of non-diabetic children 63 and diabetic and non-diabetic adults, 64 demonstrating a direct association between blood glucose level and arterial blood pressure. Some glycaemic intervention studies have shown an increase in systemic blood pressure after days/weeks of hyperglycaemia, 59, 65 whereas this was not demonstrated by others. 66 A study in early Type 2 diabetes showed dramatic increases in blood pressure in response to two hours of hyperglycaemia, but the study was performed without an euglycaemic control period. 67 Two studies finding evidence of renal 50 and systemic 49 RAS activation after 12 hours of moderately elevated blood glucose also demonstrated a substantial increase in mean arterial blood pressure. Existence of a direct link between metabolic and systemic haemodynamic factors would certainly contribute to the understanding of mechanisms underlying the toxic effects of glucose. Therefore, we decided to perform a randomised single-blinded cross-over study to test the impact of short-term hyperglycaemia on systemic blood pressure and regulatory hormones (including RAS components) in Type 1 diabetic patients without signs of diabetic neuropathy or elevated urinary albumin excretion. 68 We included 18 patients and clamped blood glucose for 90 minutes at both 5 mmol/L and 15 mmol/L in random order, using a glucose-insulin clamp technique. 68 The study demonstrated that short-term hyperglycaemia caused a modest increase of 3 mmHg in systolic blood pressure, unchanged diastolic blood pressure, extra-cellular and plasma volume expansion, in addition to suppression of the RAS and sympathetic nerve system. 68 A rise in systolic blood pressure of this magnitude may be of importance for the initiation and progression of diabetic complications, owing to impaired autoregulation of blood flow to various tissues and organs, [69] [70] [71] [72] causing downstream transmission of flow/pressure. Together with the studies by Miller, 49, 50 in which blood glucose was elevated to approximately 10 mmol/L, our study 68 in blood pressure, are dominant when blood glucose is moderately increased. Higher glucose levels increase plasma/extra-cellular volume by osmotic forces and thus turn on a strong volumedependent deactivation of the RAS, which counter-regulates the initial increase in blood pressure. It is likely that the acute volume expansions seen in our study will wear off with time, owing to osmotic diuresis and the other counter-regulating mechanisms observed. How the RAS will respond to such sustained hyperglycaemia with glucosuria and the resulting blood pressure reaction should be further investigated.
Summary
Glucose-induced activation of the intrarenal RAS may in part explain some of the deleterious impact of hyperglycaemia on the initiation and progression of diabetic nephropathy. A direct effect of glucose on systemic blood pressure and the circulating RAS may also exist. Superimposed on this, the renal RAS is further up-regulated as a non-specific response to the glucose-mediated haemodynamic and non-haemodynamic alterations in the kidney, initiating a vicious circle leading to destruction of kidney tissue and function. Interruption of these damaging processes can be achieved by blocking the RAS with ACE-I or ARBs, which delay (but do not prevent) the development of ESRD. Genetic and non-genetic factors influencing intrarenal RAS activity are likely to influence renal survival.
Genetic variation and progression of diabetic nephropathy
A genetic influence on progression of diabetic renal disease was first indicated in a small family study by Seaquist, 73 demonstrating that 12/29 siblings to patients with kidney transplantation also had ESRD.A recent review by Schelling et al. 74 summarise the general evidence of a genetic component in ESRD, based on the family clustering and diversity in incidence between ethnic groups. The aim of this part of the review is to describe the influence of specific genetic polymorphisms on the progression of established diabetic nephropathy. This will focus on the loss of kidney function once patients have developed albuminuria of more than 300 mg/24 hours. Information from studies dealing with the initiation of micro-and macroalbuminuria, where the GFR is still normal, will be mentioned only briefly. A complete review of the evidence of major genetic factors in the development of diabetic nephropathy has been provided by Tarnow 75 and Krolewski. 76 The distinction between initiation and progression may seem far-fetched, since many of the processes are related. On the other hand, different deleterious processes assume different importance in various stages of diabetic nephropathy, e.g. improved metabolic control has a highly significant impact on the development 77,78 but effects on progression of nephropathy are much less clear. 2 Furthermore, activation of the RAS is accelerated as diabetic nephropathy progresses, as discussed earlier.
Methodological aspects of genetic studies
The last decade's completion of the draft sequence of the human genome 79, 80 and related developments in methods have resulted in a large amount of research in genetics in relation to diabetic complications. Two main approaches are available to identify specific susceptibility loci (part of the DNA relevant to a particular disease) in diabetic nephropathy.
The first strategy assumes that the nature, as well as the location, of the putative gene/loci is unknown. It involves the principles of genome screening in family members with and without a phenotype for a specific trait (disease). Basically, it defines which part of the DNA (a locus) is seen most frequently together with the affected phenotype, using known DNA markers (segregation analysis). In theory, this is the most systematic approach to find major gene effects.
The second strategy is the candidate gene approach. It is based on physiological considerations or information from patients or animal models leading to selection of potential genes/loci, followed by the search for significant variations in them.This method can be performed in families, using linkage analysis, or in populationbased association studies. The main limitation to this approach is the risk of choosing wrong focus, owing to lack of understanding of pathophysiologic mechanisms.
For the study of progression of diabetic nephropathy the genome screening strategy, together with a family approach in the candidate gene strategy are strong, 75, 76 but require a substantial number of sib-pairs concordant for diabetes and diabetic nephropathy. Only in these sib-pairs is it possible to differentiate genetic variation between "fast progressors" and "slow progressors" of renal disease from genetic effects on development of diabetes and initiation of diabetic nephropathy. Such families are very infrequently observed using these stringent phenotypic criteria and consequently these studies are few in number.
An alternative is the study of patients with diabetic nephropathy and both their parents (triostudies). The co-segregation of genotypes and nephropathy variant (slow or fast progressing) can supply valid information (transmissions disequilibrium testing), but requires heterozygous parents to be informative. Again, due to limited access to families, such studies are rare.
The alternative to family studies is a population-based approach, either as case-control studies or as follow-up studies. As discussed below, the majority of studies in diabetic nephropathy are case-control studies, comparing genotype frequencies in different phenotypes, the so-called population-based association approach.The advantage of this design is in the investigation of diseases with several minor genetic effects, in addition to the relative easy access to patient populations and the lack of need for follow-up. Unfortunately, serious concerns regarding this type of study in the investigation of complex disease have been raised. 81 The design carries the risk of bias owing to: 1) 
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Mixture of populations, both within cases and controls and between groups 2) Poorly defined phenotypes 3) Selection bias 4) Selective dropout, especially in conditions in which mortality and morbidity is high, as in diabetic nephropathy. Consequently, population-based association studies should not be the only approach, but rather part of a strategy which also involves other complementary designs, as well as the investigation of underlying mechanisms. 81, 82 Prospective follow-up studies looking at genetic variations and clinical outcome give additional valuable information, but have other limitations. Finally, it should be emphasised that the expectations to discover strong genetic influences in complex diseases are hard to fulfil; the progression of diabetic nephropathy, for example, is likely to be a consequence of multistage processes and the cumulative effects of several genetic variants and non-genetic risk factors, several of which are also commonly found in individuals in the absence of the disease (incomplete penetrance). Perhaps owing to environmental influences, some patients without genetic predisposition will also develop ESRD.
Pharmacogenetics
One subject of the study of genetic influence on progression of diabetic nephropathy is a specific genetic interaction with drug responses, called pharmacogenetics. 83 The basic concept is simple: a drug interacts with its target, for instance an enzyme or a receptor. When genetic alteration leads to modified target availability or function, the drug response is modified as well. However, this principle also involves more complex relationships, such as the interplay between several genetic sites during therapy and the direct effects of drugs on gene transcription etc.This topic will be discussed below. Pharmacogenetics is particularly relevant in diabetic nephropathy, since a variable response to antihypertensive treatment is common and the majority of patients are treated with several different drugs.
Polymorphisms in the renin-angiotensin system
Angiotensin-converting enzyme In accordance with the role of RAS activation in diabetic nephropathy, an increased circulating level of ACE was demonstrated more than 20 years ago in diabetic patients with micro-vascular complications. 60 The findings were later confirmed in two subsequent studies of Type 1 diabetic patients with diabetic nephropathy. 61, 62 This identified the ACE gene as a susceptibility locus for nephropathy in diabetic patients. In 1990, Rigat et al. 84 reported the discovery of an insertion/deletion polymorphism in the ACE-gene with a relationship to the serum level of ACE, accounting for 47% of the inter-individual variation in 80 healthy subjects. It turned out to be a DNA sequence of 287 base pairs either present (insertion allele) or absent (deletion allele) in the non-coding part of chromosome 17 (intron 16) and it was named the ACE/ID polymorphism. Healthy individuals 84 and patients with diabetic nephropathy 62 carrying the DD genotype were shown to have the highest circulating ACE levels, the II carriers the lowest and ID patients intermediate levels. To gain information about the functional significance of the ACE/ID polymorphism, Hunley et al. 85 sequenced the inserted DNA string. Homology between 13 base pairs in the "insert"and a known negative regulator element was interpreted as the possible mechanism of lower ACE generation in the presence of the I allele. 85 Recently, strong evidence for a potential role of the ACE/ID polymorphism in kidney disease became available, when Mizuiri et al. 53, 86 demonstrated the highest gene expression of ACE and evidence of increased ACE levels in kidney biopsies from normal subjects with DD genotype, intermediate ACE levels in ID and the lowest expression in II carriers.
The ACE/ID polymorphism in development of diabetic nephropathy
An association between the D allele and the development of diabetic nephropathy has been proposed by three recent meta-analyses, although there may be variation in the magnitude of the effect in patients with different types of diabetes and different ethnic origins. [87] [88] [89] The odds ratio for elevated albumin excretion in Caucasian Type 1 diabetic patients with II genotype, versus ID+DD patients, was 0.72 (0.51 to 1.01), indicating a minor protective genetic effect of the I allele. 89 In addition, prospective and cross-sectional studies in Type 1 and in Type 2 patients with microalbuminuria have suggested an association between the D allele and more severe structural kidney changes. 90, 91 The ACE/ID polymorphism in progression of diabetic nephropathy The first indications of the importance of the ACE/ID polymorphisms in relation to a decline in kidney function came from studies in patients with IgA nephropathy. 92, 93 Based on these observations, we proposed the following hypothesis: The ACE/ID polymorphism predicts the therapeutic efficacy of ACE-I treatment on the decline in kidney function in Type 1 diabetic patients with diabetic nephropathy.
We studied ACE-I-treated patients, since: 1) the demonstration of the renoprotective effect of ACE-I had caused implementation of this treatment as standard therapy in Type 1 patients with diabetic nephropathy 2) the ACE/ID polymorphism directly influences circulating levels of ACE, the component targeted by the ACE-I (pharmacogenetic).We decided to test the hypothesis in both long-term and short-term observational follow-up studies. Initially, we demonstrated that, in 35 Type 1 patients with diabetic nephropathy, patients carrying the DD genotype had a loss of GFR of 5.7 ml/min/year during seven years of ACE-I, compared with 2.6 ml/min/year in patients with the ID and II genotype (p=0.01). 94 The effect of the DD genotype was independent of other risk factors for decline in GFR. 94 
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Our short-term study was performed in 60 Type 1 diabetic patients with diabetic nephropathy during the initial six months after starting ACE-I treatment. 95 Since initial reduction in albuminuria and blood pressure predicts the long-term treatment efficacy, especially during RAS blockade, these variables were primary outcomes measures. Patients were either previously without any antihypertensives (n=44) or had their antihypertensive treatment withdrawn for at least one month prior to initiation of ACE-I treatment (n=16). 95 The main findings in the study were: Patients with the II genotype had a significantly more pronounced anti-albuminuric and antihypertensive response to ACE-I than patients carrying the D allele (decline in albuminuria (II/ID/DD): 61/22/31%, p<0.01; decline in mean arterial blood pressure: 12/5/8 mmHg, p=0.02 for II vs. ID). Adjusting for differences in reduction in blood pressure did not change the impact of the ACE/ID on the decline in albuminuria. 95 Our short-term study was compatible with the EURODIAB Controlled Trial of Lisinopril in Insulin Dependent Diabetes (EUCLID). 96 This large randomised controlled trial of 530 mainly normo-albuminuric Type 1 diabetic patients receiving ACE-I or placebo for two years, demonstrated a decline in urinary albumin excretion in II genotype patients and not in the other genotypes. 96 The two initial studies 94, 95 were in agreement with the concept that patients with the DD genotype are more resistant to the renoprotective effects of ACE-I treatment than II genotype patients.
To further explore the relationship between the ACE/ID polymorphism and decline in kidney function, we investigated a subset of patients suffering from overt diabetic nephropathy having persistent normotension without antihypertensive treatment. Only in this subgroup could we explore the genetic influence during the natural history of the disease without pharmacological intervention. At that time, this patient category accounted for ~20-25% of Type 1 diabetic patients with diabetic nephropathy 16, 97 and patients were characterised by a very slow loss of GFR (1.2 ml/min/year). 98 We were not able to detect any difference in decline in GFR according to the ACE/ID polymorphism. 98 This study indicated that either the genetic influence of the ACE/ID polymorphism is specifically present during ACE-I therapy, or it may be related to blood pressure level and degree of decline in renal function and thus not detectable in our study.
Another group has demonstrated an insignificant trend towards a deleterious effect of the D allele in 86 Type 1 patients, 99 but in this study differences in types and doses of antihypertensive treatments (especially ACE-I) between genotypes were not accounted for, causing potential bias of the results. A small prospective study including 24 Type 1 patients with diabetic nephropathy 100 and a small family study using trio analysis 101 did not have the power to detect a genetic impact on progression of albuminuria to ESRD. In 56 Type 2 diabetic patients, a deleterious impact of the D allele on loss of calculated creatinine clearance and mortality has been reported. 102 In a retrospective follow-up study of 359 Type 2 diabetic patients, the authors showed a reduced renal survival time from onset of diabetes in patients with the DD genotype. 103 Casecontrol studies of the impact of the ACE/ID genotype on progression of diabetic nephropathy have shown conflicting results, [104] [105] [106] [107] [108] [109] [110] [111] but, as discussed earlier, this design has limitations. As recently reviewed, 112, 113 studies of non-diabetic renal disease reached conflicting conclusions with respect to the impact of the ACE/ID polymorphisms in patients both with and without ACE-I treatment.
In the literature published up to 2001, there were indications of a role of the ACE/ID polymorphism in the progression of diabetic nephropathy, but, especially in Type 1 patients with diabetic nephropathy, our original observations had not been confirmed. We decided to retest our initial hypothesis in a well-defined, homogenous population with considerably more statistical power. In addition, we included the evaluation of two other RAS polymorphisms and focussed on the genetic interaction between the three loci. 13 The new observational study consisted of all Type 1 diabetic patients with diabetic nephropathy at Steno Diabetes Center who were treated with ACE-I and who had a follow-up period of at least three years after the introduction of this therapy in 1985 (n=169). 13 In addition to non-genetic risk factors, we found a deleterious impact of increasing number of D alleles on the time to doubling of serum creatinine or ESRD during ACE-I, after correction for other risk factors, in a Cox proportional hazard model (effect of one additional D: risk ratio 1.81 [95% CI: 1.09 to 3.03, p=0.02], 13 see Figure 2 ). Interestingly, we also saw a genetic interaction involving the D allele and loss of kidney function (see below). 13 The study therefore confirmed and extended our original demonstrations by finding an association between the D allele and an increased frequency of doubling of serum-creatinine and ESRD during ACE-I therapy. 13 We were REVIEW not able to detect any single gene effect of the ACE/ID polymorphism on decline in GFR. This is probably due to the well-established large interindividual variation in the decline in GFR, also within each genotype, 13 which makes differences difficult to detect.When the rate of decline in GFR is relatively slow, as in our studies (~4 ml/min/year), a time-to-event analysis has greater statistical power to detect differences than an analysis based on the slope of GFR. 114 Similar findings have been demonstrated in The Ramipril Efficacy In Nephropathy Trial and The Modification of Diet in Renal Disease Study of nondiabetic nephropathies. 115, 116 In addition, the discrepancies with regard to loss of GFR between our initial findings 94 and the last study 13 could have several explanations: Genetic effects may have been more prominent in the initial study. 94 In the first study, the diastolic blood pressure was ~4 mmHg higher during the follow-up, despite a slightly higher dose of captopril (~70 mg vs.~50 mg daily), indicating more aggressive disease. 94 Higher ACE-I doses in the latter study may have reinforced differences between genotypes if DD carriers are more resistant to treatment.The effect of ACE-Is is reduced and the renal vascular response to angiotensin I are enhanced by high dietary sodium intake in the DD patients, but not in the other genotypes. 117, 118 Consequently, differences between genotypes are aggravated by a high sodium diet. Unfortunately, we do not have information regarding sodium excretion in the two studies, but since advice on a low sodium intake was applied in the clinic from the mid 1990s, a possible difference might exist between the studies. The distribution of RAS polymorphisms other than the ACE/ID may have been unbalanced in the small studies 94, 95 leading to an overestimation of the effect of the DD genotype due to interaction between RAS polymorphisms (see below). Finally, the former studies 94,95 may have overestimated the genetic effect as a consequence of a Type 1 error. It is possible that the effect of the D allele is particularly important during established renoprotective treatment in Type 1 patients with diabetic nephropathy, since ACE-I itself could reinforce the diversity between genotypes. As mentioned, patients with the D allele have higher circulating ACE levels without antihypertensive treatment. These differences may become even more prominent when production of ACE increases, as seen during chronic ACE-I therapy. 119 Unfortunately, no studies have investigated ACE levels during ACE-I treatment according to the ACE/ID polymorphisms. Whether patients with the DD genotype should be treated with ARBs to overcome this difference in treatment response, as suggested recently, 120,121 needs further investigation, since no studies have included both comparisons of ACE-I and ARBs and the relation to ACE/ID within treatments.
Whether the ACE/ID polymorphism is a marker of a nearby locus or the actual functional site has not been established. It is noteworthy that more than 10 polymorphisms in the ACE gene have now been described, although a high extent of linkage disequilibrium exists. 122 None of the other polymorphisms are known to explain more of the variation in plasma ACE than the ACE/ID polymorphism. If the ACE/ID is a genetic marker, this might account for the discrepancies seen in case-control studies carried out in different populations, since markers are more likely to distribute differently than functional polymorphisms. 81 In summary, our observations and other available data support a deleterious effect of the ACE/ID polymorphism on progression of diabetic nephropathy during ACE-I treatment and the effect is likely to be mediated through increased levels of ACE and local/systemic RAS activation. The magnitude of the genetic impact remains to be established in large prospective trials including hard renal endpoints. Clinical consequences at the current stage may be genotyping of all patients with diabetic nephropathy, followed by aggressive treatment of non-genetic risk factors in patients carrying the D allele. Additional searches for specific therapy for these patients are needed.
Angiotensinogen
Inspired by the studies of the ACE/ID polymorphism, research has also focussed on susceptibility loci in other RAS components (Figure 1 ). Initially, a correlation between plasma angiotensinogen and blood pressure was described in man. 123 A mutation in the angiotensinogen gene leading to encoding of the amino acid threonine instead of methionine (angiotensinogen-M235T), was associated with increased plasma levels of angiotensinogen and hypertension. 124 The underlying mechanism of the effect of angiotensinogen-M235T on plasma angiotensinogen has been suggested to involve linkage disequilibrium with a polymorphism in the promoter region of the gene influencing transcription rate. 125 In addition, a blunted renal vascular response to Ang II was associated with the T allele of angiotensinogen-M235T polymorphism. 126 The encouraging primary associations of this polymorphism with plasma angiotensinogen levels and essential hypertension were later questioned in other studies. 127, 128 Furthermore, a relationship with hypertension was not seen in Type 1 diabetic patients, as reviewed by Tarnow. 75 Of particular interest, one study 129 demonstrated that hypertensive patients with the T allele have a greater blood pressure reduction during ACE-I treatment,which suggests a more complex relationship and even a protective role of the T allele during renoprotective treatment. With regard to the development of diabetic nephropathy, an association with the angiotensinogen-M235T seems unlikely at present. 75 With respect to progression of diabetic nephropathy, we found no single gene effects of the angiotensinogen-M235T during ACE-I treatment. 13 This is in accordance with previous reports in case-control studies 101, 105 and a small prospective study 100 in Type 1 and Type 2 diabetic patients, 104, 109 but in contrast to a small case-control study of Type 1 patients. 110 
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In summary, no convincing evidence of a single gene effect of the angiotensinogen-M235T gene on loss of kidney function in diabetic nephropathy exists. Either the polymorphism is not in linkage disequilibrium with the variant influencing angiotensinogen expression, or the genetically determined differences in angiotensinogen levels are not sufficient, per se, to alter the clinical cause of diabetic nephropathy.
Angiotensin II Type 1 receptor
Until now, most of the unfavourable actions of Ang II were thought to be mediated through the Ang II Type 1 (AT 1 ) receptor. 130 Attention has therefore focussed on this susceptibility locus in both cardiovascular and renal disease.The gene coding for the AT 1 receptor contains 5 exons and 4 introns. The coding region is located in the fifth exon, whereas the first four exons encode 5′ untranslated sequences. Bonnardeaux et al. 131 screened the entire coding region (exon 5) and the 3′ untranslated region, and found five polymorphisms. Of these, only the variant corresponding to a substitution of C for A at position +1166 in the 3′ untranslated region (A 1166 →C) was significantly more frequent in hypertensive subjects than in normotensives. 131 Underlying effects on the receptor associated with this polymorphism have been difficult to find. No effect on receptor affinity or number of binding sites were demonstrated in human platelets. 127 Although the method has several limitations, this indicates linkage disequilibrium with an adjacent gene. On the other hand, the regulation of expression of the receptor may be tissue specific and influenced by disease status. Functional studies using ARBs and infusion of Ang II in normal subjects have indicated a diverse response between patients with various genotypes. 132 The authors interpret these findings as an augmented Ang II activity in the presence of C allele, 132 but the hypothesis needs further investigation. 132 In addition, the same authors found an increased pressor response to hyperglycaemia in patients with the C allele, which suggests a relative lower RAS activity in patients with the C allele and diabetes, 133 in whom the RAS is already triggered. 2, 50 Subsequent studies of an association between the receptor polymorphism and essential hypertension and other non-renal cardiovascular diseases have been conflicting, as reviewed by Duncan et al. 134 In most studies of the development of diabetic nephropathy, an association with the A 1166 →C polymorphism was not demonstrated, although family studies using segregation analysis have indicated a disease locus in the region, as reviewed by Tarnow. 75 We did not see any single gene effects of the AT 1 receptor (A 1166 →C) polymorphism on loss of GFR in our long-term follow-up study of ACE-Itreated Type 1 diabetic patients. 13 One study of Japanese Type 2 diabetic patients has reported an impact of the C allele on progression of diabetic nephropathy in a small number of women, 103 whereas three case-control studies 101,104,105 did not find any association between the AT 1 -receptor (A 1166 →C) polymorphism and impaired renal function in diabetic patients. This complexity is emphasised by a study of Caucasian men with IgA nephropathy, which demonstrated a negative effect of the AA genotype (AT 1 receptor A 1166 →C) on time to ESRD in the subset of patients with hypertension, although this relationship disappeared when controlling for baseline serum-creatinine and proteinuria. 135 In summary, our large observational follow-up study 13 extends the information from earlier studies, demonstrating no single genetic effects of the AT 1 (A 1166 →C) polymorphism on progression of diabetic nephropathy. An association between the polymorphism and receptor number/function still remains to be demonstrated.
Genetic interaction and pharmacogenomics
Genetics is the study of single genes and their effects. "Genomics" is the study not just of single genes, but of the function and interactions of all the genes in the genome. 136 Similarly, pharmacogenomics is the intergraded effects of the genome on drug response. 137, 138 We proposed the hypothesis that the well-known polymorphisms in the RAS may exert a combined effect beyond what is expected from their individual gene effects, resulting in a phenotype with poorer prognosis in diabetic nephropathy. Recently, Savage et al. 139 demonstrated an example of this concept in insulin resistance, another complex disease in humans. When looking at the three independent RAS polymorphisms described above, 27 combinations of genotypes are theoretically possible. Therefore, a study systematically investigating the genetic interaction would require a very large study population. Instead, we introduced an interaction analysis in our final study performed during ACE-I treatment, 13 where variation in three polymorphisms was reduced to one variable, resulting in an increased statistical power.This analysis was based on identification of three potential "bad" alleles, one within each polymorphism. Selection of the M (angiotensinogen-M235T), D (ACE/ID) and A (angiotensin II receptor A 1166 →C) as potential "bad" alleles was done in the statistical model of single gene effects on loss of GFR, even though no single gene effects were demonstrated. The total number of "bad" alleles in each patient (range: 0-6) were added together and treated as one variable in the statistical model. 13 Our analysis was corrected for other progression promoters and demonstrated an additional reduction in GFR of ~0.5 ml/min/year during ACE-I for each additional M/D/A allele. 13 This effect was comparable to the deleterious effect on kidney function of an increase in mean blood pressure of 5 mmHg or 0.8% increase in haemoglobin A 1C . In addition, a Cox regression model corrected for other factors revealed an increased risk of doubling of serumcreatinine or ESRD of 42% (rate ratio 1.42, 95% CI [1.07-1.88], p=0.015) per M/D/A allele, 13 (Figure  3) . In other words, two independent analyses indicated an impact of this composite genetic index. 13 Our findings of the genetic interaction are 105 However, analysing the published data 105 with regard to an association between the D and T allele and impairment of renal function, the relationship was not significant. Furthermore, only half of the patients in this study 105 were treated with ACE-I. As mentioned, ACE-I may aggravate the differences between genotypes. In accordance with our findings, two earlier studies, including 260 110 and 168 140 Caucasian patients with various non-diabetic renal diseases, reported a deleterious effect of the D allele on loss of renal function only or particularly present in patients with the MM genotype of the angiotensinogen-M235T polymorphism. In contrast, Bantis et al. 141 found a negative impact of the combination of D and T alleles on loss of calculated deterioration of renal function in patients with IgA nephropathy (n=44). Studies of single gene effects on the response to RAS blockade in hypertensive patients 129 and in patients with hypertension and left ventricular hypertrophy 142 supports the identification of the M allele of the angiotensinogen-M235T and the A allele of the AT 1 -receptor (A 1166 →C) polymorphisms as risk alleles. Since existing results are conflicting and our interaction model is a novel concept, our study may serve a hypothesis-generating purpose, but needs to be confirmed in other prospective studies.
As to the underlying mechanisms of the genetic interaction, one possibility is that there is some (ACE/ID) or no effect (angiotensinogen-M235T or AT 1 -receptor A 1166 →C) on disease progression when only one "hit" in the RAS is present. One could speculate that up-regulation in one component of the RAS is compensated by downregulation in other components, causing little overall activation. If the level or function of several components of the RAS is simultaneously changed, the system is not able to compensate and the system becomes synergistically activated. In addition, the polymorphisms may themselves alter gene regulation (ACE/ID), changing sensitivity to feedback from the other RAS components. Alternatively, mechanisms may involve linkage disequilibrium with other sites.
In summary, we have demonstrated a complex genetic influence on loss of renal function in diabetic nephropathy.Three polymorphisms in different key components of the RAS act synergistically, resulting in a deleterious renal outcome.The deletion allele of the ACE/ID polymorphism is likely to be within a primary susceptibility locus and the other polymorphisms within loci reinforcing the impact of the D allele. Our findings need to be confirmed and mechanisms explaining the possible interaction between the RAS polymorphisms remain to be clarified. New methods to investigate the complexity of genetic interactions should be developed in the near future.
Genetic polymorphisms outside the reninangiotensin system
The human plasma-cell membrane antigen (PC-1) Insulin resistance has been demonstrated in Type 1 diabetic patients with elevated urinary albumin excretion 143 and in their first degree relatives, 144 and has been suggested to influence vascular damage as occurs in diabetic nephropathy. 145 The human plasma-cell membrane differentiation antigen (PC-1) inhibits insulin receptor signalling [146] [147] [148] [149] [150] and is involved in insulin resistance. [147] [148] [149] Functional and population-based studies have demonstrated an association between an amino acid variant in the glycoprotein PC-1 (lysine to glutamine at codon 121: K121Q) and insulin resistance in some populations, [151] [152] [153] although this was not confirmed in a Danish study. 154 De Cosmo et al. have found an association between this genetic variant (Q allele) and a faster progression of diabetic nephropathy, as estimated by calculated creatinine clearance, in 77 Type 1 diabetic patients. 155 In addition, the same authors reported an interaction between the Q allele and the DD genotype of the ACE/ID polymorphism in a combined Italian/British population. 156 The studies had limitations in methods; especially since loss of calculated creatinine clearance is an indirect measure of loss of kidney function.We therefore decided to test the effect of the PC-1 (K121Q) variant on decline in GFR, measured by 51 Cr-EDTA plasma clearance technique, in our large homogenous group of Type 1 diabetic patients with diabetic nephropathy (n=297). 157 The result of our study did not confirm the deleterious single gene effect of the Q allele on GFR or time to development of ESRD 157 nor the interaction with the D allele of the ACE/ID polymorphism (not published). A very recent combined case-control and family-based study demonstrated an association with the development of macroalbuminuria, but did not find an overall difference in frequency of the Q allele in patients with albuminuria compared with patients with ESRD. 158 On the other hand, and in contrast to our findings, indications of an impact of the Q allele on early onset of ESRD (regarded by the authors as indirect measure of rate of progression) was demonstrated. 158 The same results were seen in families when using transmissions disequilibrium test. 158 In summary, the K121Q amino acid variant of the human plasma-cell membrane differentiation antigen has not been established as a genetic risk factor in diabetic nephropathy. Conflicting results may be due to insufficient methods and diversity in genetic background between study populations, and therefore more studies are needed.
Other susceptibility genes
Endothelial nitric oxide synthase (eNOS), found in the vasculature, catalyses the production of nitric oxide (NO) from L-arginine. The NO diffuses across the endothelium into smooth muscles and causes vasodilation. As reviewed by Klahr, 159 NO also has other beneficial effects in local tissue and insufficient NO may play a role in renal disease progression. Disruption of the eNOS gene in mice has been shown to induce hypertension 160 and several sequence differences in the eNOS gene are reported to have an association with various cardiovascular diseases in man, as recently reviewed. 161 The region of the eNOS gene has been linked with diabetic nephropathy in Pima Indians with Type 2 diabetes. 162 In a combined casecontrol and family-based study, Zanchi et al. 163 demonstrated an association between two different eNOS polymorphisms and impaired renal function/ESRD in Type 1 diabetic patients with diabetic nephropathy. Recently, a different polymorphism in the eNOS gene, with functional effects on NO production, was associated with ESRD in Japanese Type 2 diabetic patients. 164 These polymorphisms should be further investigated. However, supporting a functional role of the eNOS gene in progression of diabetic nephropathy is the demonstration of different polymorphisms across the gene which seems to be associated with poor renal prognosis.
Several other susceptibility genes have been suggested in diabetic and non-diabetic renal disease, but proofs and underlying mechanisms have not been established. Decorin is a proteoglycan in the extracellular matrix involved in the regulation of expression and activity of transforming growth factor beta (TGF-β). 165, 166 As mentioned earlier, local tissue TGF-β mediates mesangial matrix expansion and glomerular sclerosis and is likely to be of key importance in the development and progression of diabetic nephropathy. 165, 167 A genetic variant in the decorin gene has been associated with slower loss of calculated creatinine clearance in Type 1 diabetic patients with diabetic nephropathy, although the functional significance of the variant is not known. 168 Further investigation of this finding is needed.
In non-diabetic renal disease,identified loci with potential impact on loss of kidney function include α-adducin, indirectly involved in renal sodium handling, and its genetic interaction with the ACE/ID polymorphism. [169] [170] [171] In addition, a polymorphism in the uteroglobin gene, an anti-inflammatory protein involved in regulation of collagen deposition, was associated with progression of IgA nephropathy. 172 The role of these genetic variants in diabetic nephropathy remains to be investigated.
Gender
As recently reviewed, [173] [174] [175] it is now well established that men with non-diabetic kidney disease have a more rapid loss of renal function than women.The effect of male gender on progression of diabetic nephropathy is more controversial, as reviewed in detail by Seliger. 174 We have addressed the topic in two of our observational studies looking at loss of GFR. 13, 98 In the study of normotensive patients, 98 we found that male gender independently predicted a steeper decline in GFR in a multivariate analysis including other risk factors for progression. In the last of our studies investigating the loss of GFR during ACE-I, 13 we confirmed that men had a more rapid decline in kidney function than women. However, the more aggressive kidney disease seen in men was associated with more pronounced albuminuria and higher blood pressure and the impact of gender disappeared after adjustment for these two other risk factors. This suggests an effect of gender via elevation of albuminuria and blood pressure in diabetic nephropathy. Potential mechanisms of the impact of gender on loss of kidney function involve both oestrogen and androgen, in addition to alterations in components of the RAS and expression of TGF-β. 174, 175 In summary, growing evidence suggests that men have a higher risk of ESRD than women, also in diabetic nephropathy. More research is necessary to investigate the underlying mechanisms and potential role of drug therapy. The clinical implication at the present stage may be the need for more aggressive antihypertensive treatment in men.
Conclusion and future strategy
At present, a genetic impact on progression of diabetic nephropathy is established. The underlying mechanisms and specific genes are only just beginning to be revealed. Until now, the search for single gene effects has been somewhat disappointing, probably owing to lack of insight into genomic processes and insufficiently precise methods. We and others have demonstrated the role of the ACE/ID polymorphism on the progression of diabetic nephropathy, presumably through changes in ACE level leading to RAS activation. Genotyping will identify patients with a high risk of early ESRD and patients carrying the D allele may be offered aggressive treatment of other risk factors until specific therapy is found. Apart from this, male gender is likely to augment the loss of kidney function, maybe mediated through higher albuminuria and blood pressure. genes have yet been confirmed as risk factors for ESRD. Indications of genetic interaction in the RAS need to be explored and the investigations expanded to involve other loci. New methods to analyse the genetic interplay based on the underlying mechanisms should be developed. The ongoing international collaborations collecting genetic material from large numbers of patients and relatives will probably reveal new insights, but large prospective studies are also necessary. As patients are exposed to polypharmacy, pharmacogenomics will become increasingly important. Functional stress tests in diabetic nephropathy, such as applying hyperglycaemia, changes in sodium intake or infusion of Ang II, may help to understand the dynamic gene effects hidden in static analysis. 133, 176 Another exciting field is the investigation of changes in genome function during disease, such as gene expression profiles in normal and abnormal tissue. 177, 178 During the forthcoming years, an enormous amount of information from the human genome will become available. It is likely that a complete new understanding of genes, their regulation and interplay will change our paradigm of complex diseases, including diabetic nephropathy. 
